Novanta (NOVT) Q3 2026 Earnings Call Transcript
Novanta (NOVT) reported Q3 2026 revenue of $305M, up 23%, with organic growth of 10%. Adjusted EBITDA rose 38% to $80M, and adjusted EPS increased 21% to $1.05. The company acquired Riverpoint Medical, expanding its medical end markets to 53% of revenue. Customer bookings grew 29%, and backlog reached $543M. Operating cash flow tripled year-over-year to $156M. Novanta expects full-year 2027 gross margin expansion and strong earnings growth, driven by new products and acquisitions.
How this was made
The 30-second read
Why it matters
The earnings beat and acquisition suggest a bullish outlook for the stock, with potential upside in the near term.
Market read
First‑time disclosure of Q3 results provides fresh data for traders; the beat may trigger buying pressure.
What to watch
Higher cash conversion may be offset by upcoming capital expenditures for new factories.
Background
Novanta reported a strong Q3 2026 performance, highlighted by a 23% revenue increase and the closing of its largest acquisition to date.
Ticker impact
Q3 2026 earnings call disclosed revenue $305M, adjusted EPS $1.05, and completion of the Riverpoint Medical acquisition.
likely upward pressure as investors price in the earnings beat and growth outlook
Revenue and EPS both exceeded guidance, margins expanded, and the acquisition adds a high‑growth medical segment.
Market effects
Strengthens the medical devices and precision robotics subsectors, potentially boosting peers.
Positive for U.S. med‑tech investors; modest effect on European suppliers.
Highlights continued demand for high‑precision medical equipment worldwide.
Counterpoint
The integration risk of Riverpoint Medical could pressure margins if synergies fall short.
Key entities
- CompanyNovanta
US‑listed med‑tech and precision engineering firm (ticker NOVT).
- CompanyRiverpoint Medical
Medical device company acquired by Novanta.
